# Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition

> **NCT00471991** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 60 (actual)

## Conditions studied

- Oral Contraceptive

## Interventions

- **DRUG:** SH T04769G
- **DRUG:** Ethinyl estradiol / dienogest (SH D00659 AF)

## Key facts

- **NCT ID:** NCT00471991
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471991, "Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00471991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*